The NF-κB/STAT3 inhibitor RTA 402 is currently undergoing phase I/II clinical testing for pancreatic cancer [155] and a phase I trial in patients with solid tumors and lymphoid malignancies has already been completed [156]. This evidence concerns the gene STAT3 and pancreatic neoplasm.